Which percentage of the DCB group had diabetes in the AGENT IDE trial?

• A. 48%
• B. 44%
• C. 51%
• D. 12%

Answer: (C)

The correct percentage of the DCB group that had diabetes in the AGENT IDE trial is significant for understanding the demographic characteristics of participants in this study. In clinical trials, particularly those assessing medical interventions, the presence of comorbid conditions like diabetes can impact treatment outcomes and disease progression. In this case, reporting that 51% of the DCB group had diabetes provides insight into how common this condition was among the participants, reflecting the population's health status and potentially influencing the results of the trial.

This percentage is important for clinicians and researchers as it helps contextualize the findings of the trial, enabling consideration of how diabetes may affect the efficacy and safety of desigintanib-coated balloon (DCB) treatments in this patient population. Understanding the prevalence of diabetes within the study cohort can assist in comparing the trial's results to other relevant research and clinical expectations.